

37. The pharmaceutical combination according to claim 26, wherein the cancer comprises one or more of BRAF mutation.

38. The pharmaceutical combination according to claim 26, wherein the cancer comprises one or more of MEK1 mutation.

39. The pharmaceutical combination according to claim 26, wherein the cancer comprises one or more of PIK3CA mutation and/or PIK3CA overexpression.

40. The pharmaceutical combination according to claim 21, wherein the cancer is resistant to treatment with an EGFR inhibitor.

41. (canceled)

* * * * *